Guardant Health announces NCCN has included Shield blood test in CRC guidelines

Guardant Health (GH) announced that the National Comprehensive Cancer Network, NCCN, has included the Shield blood test in its updated colorectal cancer, CRC, screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA, ctDNA. The updated NCCN CRC Screening Guidelines reflect the addition of Shield with a recommendation for testing every three years. “With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of eligible Americans who are forgoing their recommended screening for colorectal cancer,” said AmirAli Talasaz, Guardant Health co-CEO. “This major guideline inclusion from the National Comprehensive Cancer Network is just the first for Shield, and we believe a pivotal step for more patients to benefit from this test.”